Catherine Skari
-
Jan- 2022 -7 JanuaryNews
SCD Drug Oxbryta Receives CHMP Positive Opinion For Approval In The EU
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending…
Read More » -
Dec- 2021 -22 DecemberNews
THALIA2018-2021 | Europe Is Seeing A Surge In Thalassaemia, Project Results Show
“Although thalassemia has always been endemic in Europe, especially in southern European countries such as Cyprus, Greece and Italy, the…
Read More » -
21 December
-
21 DecemberNews
TIF Article: COVID-19 Pandemic Exacerbated Existing Problems With Thalassaemia Care
The article discusses how the COVID-19 pandemic has magnified challenges in thalassaemia care worldwide and underscores TIF’s activities throughout the…
Read More » -
Jun- 2019 -12 JunePatients’ stories
FROM PUMP TO PILL by Chanapa Tantibanchachai
Winner Story #1 – International Thalassaemia Day 2018 ”As I reflect on my past, present and future as a…
Read More » -
Aug- 2022 -3 AugustNews
NEW PUBLICATION | Short Guide For the Management of TDT (2nd Edition)
The 4th edition of the original full-length Guidelines, published in June 2022, includes a full review of the evidence supporting…
Read More » -
Jun- 2019 -12 JunePatients’ stories
مييا حمااكة واقعي مع الثالس by Hanady Alsanwi
Winner Story #2– International Thalassaemia Day 2018 متكرر ما بني الفرتة واألخرى ونظرات ً ال يفارق جسدي ونقل دما…
Read More » -
12 JunePatients’ stories
LET’S MOVE TO A BETTER FUTURE by Siti Nur Azilayati Rahmah Raman
Winner Story #3 – International Thalassaemia Day 2018 ”My family living in the rural area because my father being assign…
Read More » -
Dec- 2021 -10 DecemberNews
TIF Guide on COVID-19 Vaccinations & Therapeutic Drugs – The December Issue
During this last fortnight, experts have scrambled to gain an understanding of the new heavily mutated variant, what kind of…
Read More » -
Jun- 2019 -6 JuneNews
A milestone in the treatment of b-thalassaemia – The 1st gene therapy for Transfusion Dependent β-Thalassaemia wins approval in Europe
Zynteglo, Bluebird Bio’s ex vivo gene therapy for β-thalassaemia, got a green light from the EMA for conditional marketing…
Read More »
